The market for plasma therapy across the globe is expected to propel significantly during the forecast period. The global plasma therapy market is expected to grow impressively with a CAGR of 13.1% during 2018-2023. The factors driving the plasma therapy market are rising prevalence of life threatening diseases which includes various neurological system disorders such as chronic inflammatory demyelinating polyneuropathy (CIPD), idiopathic thrombocytopenic purpura (ITP), multifocal motor neuropathy (MMN). In addition, the rise in the occurrence of contagious diseases such as hepatitis A&B, tetanus and rabies is estimated to impact the market positively during the forecast period.
Get Free Sample Copy @ https://www.omrglobal.com/request-sample/plasma-therapy-market
With an impressive technological advancement over the period has added much more to the therapies for treatment of various diseases which has also led to introduction of cost effective protein fractioning technologies from plasma. This is also being seen as a major booster to the growth within the plasma therapy market during the forecast period. As per estimates by WHO about 108 million global blood donations come from the high-income countries, which is the home for 18% of the world’s population. Presence of favourable government initiates for the development of plasma derived medicine and rising awareness regarding the importance of blood donation are the key drivers for this market.
Browse for Full Report Description@ https://www.omrglobal.com/industry-reports/plasma-therapy-market
On the geographical forefront, North America is a leader held the market share in 2017 which is expected to sustain during the forecast period as well. This is mainly due to the growing number of hospitals and clinics which is increasing the demand for the plasma derived from proteins. They key driving forces expected to boost the market of plasma therapy in North America are rising awareness levels among the blood donors, presence of advanced protein fractioning procedures, and higher per capita income in the developed countries. Furthermore, APAC region is also considered to be fastest growing region mainly due to growing medical tourism, technological advancement, rising disposable income of the patients, rising healthcare practitioner’s awareness, and increasing government initiatives pertaining to the development of plasma protein medicines are expected to fuel the demand of plasma protein product. The report includes detailed market overview, market determinants, company profiling, sector analysis, market segmentation, geographical analysis, strategic recommendations, key company analysis, key findings, market estimations, market insights, analyst insights and predictive analysis of the market.
MARKET SEGMENTATION
PLASMA THERAPY BY SOURCE
- AUTOLOGOUS
- ALLOGENIC
PLASMA THERAPY BY APPLICATION
ORTHOPAEDICS
- ARTHIRITIS
- BONE REPAIR AND REGENERATION
- CHRONIC TENDINITIS
CARDIAC MUSCLE INJURY
DERMATOLOGY
- ANDROGENIC ALOPECIA
- PLASTIC SURGERY
DENTAL
NERVE INJURY
OTHER APPLICATIONS
PLASMA THERAPY BY TYPE
- LEUKOCYTE-RICH FIBRIN
- PURE PLATELET-RICH FIBRIN
- LEUKOCYTE-RICH PRP
- PURE PRP
PLASMA THERAPY BY END USERS
- HOSPITALS AND CLINICS
- RESEARCH INSTITUTES
- OTHERS
COMPETITIVE LANDSCAPE
- KEY COMPANY ANALYSIS
- KEY STRATEGIES
REGIONAL ANALYSIS
NORTH AMERICA
- UNITED STATES
- CANADA
EUROPE
- UNITED KINGDOM
- FRANCE
- GERMANY
- ITALY
- SPAIN
- REST OF THE EUROPE
ASIA PACIFIC
- INDIA
- CHINA
- JAPAN
- REST OF THE ASIA PACIFIC
REST OF THE WORLD
COMPANY PROFILES
- BAXTER INTERNATIONAL
- BIOLIFE PLASMA SERVICES
- BIOTEST
- BIO PRODUCT LABORATORY LTD. (BPL)
- CAMBRYN BIOLOGICS LLC
- CSL LTD.
- CHINA BIOLOGIC PRODUCTS, INC.
- GRIFOLS INTERNATIONAL S.A.
- KEDRION S.P.A.
- LFB SA
(This release has been published on OMR Industry Journal. OMR Industry Journal is not responsible for any content included in this release.)
